Page last updated: 2024-09-04

lonafarnib and Cholera Infantum

lonafarnib has been researched along with Cholera Infantum in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barker, J; Colombat, P; Cortes, J; DeAngelo, DJ; Feldman, EJ; Frank, E; Guilhot, F; Holyoake, T; Kirschmeier, P; Lipton, JH; List, A; Loechner, S; Maloisel, F; Martinelli, G; Nielsen, JL; O'Brien, SG; Petersdorf, S; Reiffers, J; Roboz, GJ; Simonsson, B; Statkevich, P; Turner, AR; Zhu, Y	1
André, M; Bosly, A; Bron, D; Debusscher, L; El Housni, H; Martiat, P; Mineur, P; Ravoet, C; Robin, V; Soree, A	1
Feldman, EJ	1

Reviews

1 review(s) available for lonafarnib and Cholera Infantum

Article	Year
Farnesyltransferase inhibitors in myelodysplastic syndrome. Current hematologic malignancy reports, 2006, Volume: 1, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Diseases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Farnesyltranstransferase; Gastrointestinal Diseases; Genes, ras; Hematologic Neoplasms; Humans; Middle Aged; Myelodysplastic Syndromes; Piperidines; Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; Treatment Outcome	2006

Article

Year

Farnesyltransferase inhibitors in myelodysplastic syndrome.

Current hematologic malignancy reports, 2006, Volume: 1, Issue:1

Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Diseases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Farnesyltranstransferase; Gastrointestinal Diseases; Genes, ras; Hematologic Neoplasms; Humans; Middle Aged; Myelodysplastic Syndromes; Piperidines; Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; Treatment Outcome

2006

Trials

2 trial(s) available for lonafarnib and Cholera Infantum

Article	Year
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia, 2008, Volume: 22, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Drug Monitoring; Enzyme Inhibitors; Farnesyltranstransferase; Gastrointestinal Diseases; Humans; Leukemia, Myelomonocytic, Chronic; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Piperidines; Pyridines; Remission Induction; Treatment Outcome	2008
Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study. Annals of hematology, 2008, Volume: 87, Issue:11 Topics: Aged; Farnesyltranstransferase; Female; Gastrointestinal Diseases; Genes, ras; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Piperidines; Pyridines	2008

Article

Year

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.

Leukemia, 2008, Volume: 22, Issue:9

Topics: Adult; Aged; Aged, 80 and over; Drug Monitoring; Enzyme Inhibitors; Farnesyltranstransferase; Gastrointestinal Diseases; Humans; Leukemia, Myelomonocytic, Chronic; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Piperidines; Pyridines; Remission Induction; Treatment Outcome

2008

Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study.

Annals of hematology, 2008, Volume: 87, Issue:11

Topics: Aged; Farnesyltranstransferase; Female; Gastrointestinal Diseases; Genes, ras; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Piperidines; Pyridines

2008